Takeda has announced US regulatory approval of oveporexton (Orzeyful) for type 1 narcolepsy, following its July 2026 approval in China. The asset is the first OX2R agonist to reach the market globally, selectively restoring orexin signalling, which is deficient in the disease.

The decision rested on two Phase III trials: FirstLight, where 1 mg and 2 mg once-daily doses increased mean sleep latency on the Maintenance of Wakefulness Test by 13.83 and 17.20 minutes versus placebo at week 12 (both p<0.001), and RadiantLight, where 2 mg added 20.09 minutes versus placebo (p<0.001), with a baseline latency near 4.5 to 5 minutes.

The approval opens a mechanistically distinct franchise outside Takeda's GI and oncology core, addressing excessive daytime sleepiness without the noradrenergic or stimulant liabilities of historical therapies. With no direct OX2R competitor yet approved, oveporexton positions Takeda in a first-mover rare-central-nervous-system niche with global pricing and access leverage, and provides a platform for potential extension into type 2 narcolepsy or other orexin-deficient disorders pending further data.